SCHEMBL20596195

SCHEMBL20596195

COc1ccc(-n2ccc(=O)c3cc(F)c(C(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)cc32)c(Cl)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAS1R3 Q7RTX0 1/20 0.32
▸ TAS1R1 Q7RTX1 1/20 0.32
▸ TAS1R2 Q8TE23 1/20 0.32
▸ NR3C1 P04150 1/20 0.32
▸ PGR P06401 1/20 0.32
▸ NR3C2 P08235 1/20 0.32
▸ GABRA1 P14867 1/20 0.32
▸ GABRG2 P18507 1/20 0.32
▸ GABRB3 P28472 1/20 0.32
▸ GABRA5 P31644 1/20 0.32
▸ GABRA3 P34903 1/20 0.32
▸ GABRA6 Q16445 1/20 0.32
▸ EGFR P00533 1/20 0.32
▸ NPC1 O15118 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ GPR35 Q9HC97 1/20 0.31
▸ CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20596259 0.81 MAOB (0.37) TAS1R3TAS1R1TAS1R2EGFRNPC1
SCHEMBL20595817 0.76 KDM4E (0.42) MAPTRAB9ALMNAKMT2AHIF1A
SCHEMBL17434691 0.68 LMNA (0.40) TAS1R3TAS1R1TAS1R2NPC1MAPT
SCHEMBL20596021 0.67 LMNA (0.41) MAPTSMN1; SMN2LMNA
SCHEMBL31057922 0.65 FPR2 (0.38) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL30145274 0.65 MARS2 (0.47) EGFRALDH1A1HPGD
SCHEMBL20595982 0.65 MARS2 (0.47) EGFRALDH1A1HPGD
SCHEMBL17466150 0.64 CA12 (0.39) NR3C2NPC1MAPTHTTRAB9A
SCHEMBL17434692 0.63 LMNA (0.37) NPC1MAPTHTTRAB9ASMN1; SMN2
SCHEMBL23121351 0.61 ATM (0.41) EGFRMAPTKMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 TAS1R3 2418/4885TAS1R1 1751/4885TAS1R2 2404/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR TAS1R3 2952/4885TAS1R1 3007/4885TAS1R2 2866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback